. Changes in serum cholyglycine and prealbumin levels, glutamyl transpetidase , and Alpha fetoprotein  after Transcatheter Arterial Chemoembolization Combined with Microwave Ablation of Liver Cancer :

Kang  Chen; Chaojie  Zhang; Feihu  Sun; Lei  Sun; Chen  Fan; Wei-Dong  Wang

doi:10.5937/jomb0-53123

Kang Chen Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214000, People’s Republic of China;
Chaojie Zhang Department of Interventional Radiology , The Affiliated Wuxi Fifth Hospital of Jiangnan University , The Fifth People’s Hospital of Wuxi, Wuxi, 214000, People’s Republic of China.
Feihu Sun Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214000, People’s Republic of China;
Lei Sun Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214000, People’s Republic of China;
Chen Fan Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214000, People’s Republic of China;
Wei-Dong Wang 1 Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi People’s Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, 214000, People’s Republic of China;

DOI: https://doi.org/10.5937/jomb0-53123

Keywords: PLC; TACE; MWA; Liver function; SR; serum cholyglycine and prealbumin levels, glutamyl transpetidase , and Alpha fetoprotein

Abstract

Introduction: It aimed to assess the clinical outcome of transcatheter arterial chemoembolization (TACE) and its combination with microwave ablation (MWA) in middle or advanced primary liver cancer(PLC), and to analyze the causes complications. Material and Method: According to the treatment methods, 100 patients with middle or advanced PLC were divided into TACE group (TACEG) and TACE+MWA group (combination group, CG) (50 cases in each). The TACEG was treated with TACE alone, and the CG adopted TACE combined with MWA. The quality of life (QoL)SF-36 score, serum liver function index, response, 1-year overall survival (OS) rate, and complication rate were observed before and following remedy. Result: As against the TACEG, following remedy, the CG had a higher SF-36 score,objective relief rate (ORR) (32% vs 50%), disease control rate (DCR)(82% vs 90%), and 1-year OS (60% vs 84%) and a lower 1-year complication rate (34% vs 16%);Following remedy, as against the TACEG, serum cholyglycine (CG) and prealbumin (PAB) levels were higher, and the levels of total bilirubin (TBil), direct bilirubin (DBil), alanine aminotransferase(ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyltranspetidase (GGT), and Alpha fetoprotein (AFP) were lower in the CG (all P<0.05). Conclusion: TACE combined with MWA is effective and safe in middle or advanced PLC, and can markedly improve liver function and postoperative survival rate(SR).

References

References
1. Yin L, Chen L, Qi Z, Li J, Wang X, Ma K, Liu X. Gene expression-based immune infiltration analyses of liver cancer and their associations with survival outcomes. Cancer Genetics, 2021;254-255(3):75-81.
2. Liu H, Tang T. Pan-cancer genetic analysis of disulfidptosis-related gene set. Cancer Genetics, 2023;278-279:91-103.
3. Hatanaka T, Arai H, Kakizaki S. Balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. World Journal of Hepatology, 2018;10(7):485-495.
4. Asano K, Kageyama K, Yamamoto A, Jogo A, Uchida-Kobayashi S, Sohgawa E, Murai K, Kawada N, Miki Y. Transcatheter arterial chemoembolization for treatment-naive hepatocellular carcinoma has different treatment effects depending on central or peripheral tumor location. Liver Cancer, 2023;12(6):576-589.
5. Liu YM, Ren YQ, Song SL, Zheng CS. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: etiological characteristics, treatment, and outcome analysis. The Kaohsiung Journal of Medical Sciences, 2023;39(1):87-94.
6. Ishikawa T, Imai M, Sato R, Jimbo R, Kobayashi Y, Sato T, Iwanaga A, Sano T, Yokoyama J, Honma T. Prognostic value of TACE with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with liver metastases from unresectable colorectal cancer. Anticancer Resesrch, 2023;43(8):3647-3651.
7. Senitko M, Oberg CL, Abraham GE, Hillegass WB, Akhtar I, Folch E. Microwave ablation for malignant central airway obstruction: a pilot study. Respiration, 2022;101(7):666-674.
8. Tomita K, Matsui Y, Uka M, Umakoshi N, Kawabata T, Munetomo K, Nagata S, Iguchi T, Hiraki T. Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade. Japanese Journal of Radiology, 2022;40(10):1035-1045.
9. Liu F, Hou B, Li Z, Zhang L, Zhou Y, Bian H, Huo Z. Microwave ablation of multifocal primary liver cancer guided by real-time 3.0T MRI. International Journal of Hyperthermia, 2023;40(1):2228519(1-7).
10. Liu H, Dilger JP, Lin J. Effects of local anesthetics on cancer cells. Pharmacology & Therapeutics, 2020;212:107558(1-13).
11. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. Journal of Hepatology, 2022;77(6):1598-1606.
12. Rumgay H, Ferlay J, De Martel C, Georges D, Ibrahim AS, Zheng R, Wei W, Lemmens VEPP, Soerjomataram I. Global, regional and national burden of primary liver cancer by subtype. European Journal of Cancer, 2022;161:108-118.
13. Wang J, Xu H, Wang Y, Feng L, Yi F. Efficacy and safety of drug-eluting bead TACE in the treatment of primary or secondary liver cancer. Canadian Journal of Gastroenterology and Hepatology, 2023;2023:5492931(1-8).
14. Schöler D, Castoldi M, Jördens MS, Schulze-Hagen M, Kuhl C, Keitel V, Luedde T, Roderburg C, Loosen SH. Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series. Plos One, 2021;16(8):e0255983(1-12).
15. Yang X, Lan T, Zhong H, Zhang Z, Xie H, Li Y, Huang W. To systematically evaluate and analyze the efficacy and safety of transcatheter arterial chemoembolization (TACE) in the treatment of primary liver cancer. Journal of Healthcare Engineering, 2022;2022(5):8223336(1-9).
16. Dang Z, Jiang L, Huang F. Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients. International Journal of Clinical Pharmacology and Therapeutics, 2023;61(10):423-429.
17. Knapen RRMM, Korenblik R, James S, Dams G, Olij B, De Boer SW, Van Dam RM, Van der Leij C. The effect of microwave and radiofrequency ablation (MWA/RFA) on liver volume in patients with primary and secondary liver tumours: a retrospective analysis. CardioVascular and Interventional Radiology, 2023;46(8):991-999.
18. Zhu C, Chen H, Fang Q, Jiang Y, Xu H. Improvement in the condition of patients with primary liver cancer with transcatheter arterial chemoembolization before and after microwave ablation interventional therapy. American Journal of Translational Research, 2021;13(10):11908-11916.
19. Zhang K, Liu M, Xu Y, He X, Sequeiros RB, Li C. Multiparametric magnetic resonance-guided and monitored microwave ablation in liver cancer. Journal of Cancer Research and Therapeutics, 2020;16(7):1625-1633.
20. Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, Huang F, Tang R, Cheng Y, Huang Z, Liang Y, Fan H, Qiao L, Li F, Zhuang W, Peng B, Wang J, Li J, Kuang M. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). Journal of Clinical Oncology, 2023;41(1):117-127.
21. Vogl TJ, Zitsch M, Albrecht M, D'Angelo T, Basten L, Gruber-Rouh T, Nour-Eldin NA, Naguib NNN. Long-term outcomes following percutaneous microwave ablation for colorectal cancer liver metastases. International Journal of Hyperthermia, 2022;39(1):788-795.
22. Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carrafiello G, Azoulay D, Petrillo A, Curley SA. Radiofrequency ablation and microwave ablation in liver tumors: an update. oncologist. The Oncologist, 2019;24(10):e990-e1005.
23. Zhang H, Wang J, Li W, Liu S, Li Z, Hu X. Microwave ablation combined with I125 seed implantation for treatment of residual lesions of liver cancer after TACE. Journal of Cancer Research and Therapeutics, 2022;18(5):1392-1396.
24. Wang P, Yang Y, Pang G, Zhang C, Wei C, Tao X, Liu J, Xu J, Zhang W, Shen Y. Hepatocyte-derived MANF is protective for rifampicin-induced cholestatic hepatic injury via inhibiting ATF4-CHOP signal activation. Free Radical Biology & Medicine, 2021;162:283-297.
25. Castera L, Laouenan C, Vallet-Pichard A, Vidal-Trécan T, Manchon P, Paradis V, Roulot D, Gault N, Boitard C, Terris B, Bihan H, Julla JB, Radu A, Poynard T, Brzustowsky A, Larger E, Czernichow S, Pol S, Bedossa P, Valla D, Gautier JF; QUID-NASH investigators. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care, 2023;46(7):1354-1362.
26. Aljobaily N, Viereckl MJ, Hydock DS, Aljobaily H, Wu TY, Busekrus R, Jones B, Alberson J, Han Y. Creatine alleviates doxorubicin-induced liver damage by inhibiting liver fibrosis, inflammation, oxidative stress, and cellular senescence. Nutrients, 2020;13(1):41(1-15).
27. Midya V, Colicino E, Conti DV, Berhane K, Garcia E, Stratakis N, Andrusaityte S, Basagaña X, Casas M, Fossati S, Gražuleviciene R, Haug LS, Heude B, Maitre L, McEachan R, Papadopoulou E, Roumeliotaki T, Philippat C, Thomsen C, Urquiza J, Vafeiadi M, Varo N, Vos MB, Wright J, McConnell R, Vrijheid M, Chatzi L, Valvi D. Association of prenatal exposure to endocrine-disrupting chemicals with liver injury in children. JAMA Network Open, 2022;5(7):e2220176(1-16).
28. Zhou Y, Lu W, Yang G, Chen Y, Cao J, Zhou C. Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease. American Journal Translational Research, 2021;13(12):13485-13497.
29. Li Y, Liu X, Jiang Y, Wan K, Liu W, Ou Y, Bai J, You Y, Hu F, Xu Z, Bie P, Zhang C, Zhang L. Low preoperative prealbumin predicts the prevalence of complications following liver transplantation. BMC Gastroenterology, 2021;21(1):233(1-9).
30. Huang L, Li J, Yan JJ, Liu CF, Wu MC, Yan YQ. Prealbumin is predictive for postoperative liver insufficiency in patients undergoing liver resection. World Journal of Gastroenterology, 2012;18(47):7021-5.
31. Zhao K, Zhou X, Xiao Y, Wang Y, Wen L. Research progress in alpha-fetoprotein-induced immunosuppression of liver cancer. Mini-Reviews in Medicinal Chemistry, 2022;22(17):2237-2243.
32. Zhou W, Yu M, Mao X, Pan H, Tang X, Wang J, Che N, Xie H, Ling L, Zhao Y, Liu X, Wang C, Zhang K, Qiu W, Ding Q, Wang S. Landscape of the peripheral immune response induced by local microwave ablation in patients with breast cancer. Advanced Science (Weinh), 2022;9(17):e2200033(1-16).
33. Wang Y, Li W, Man W, Dong X, Luo Y, Zhang Y, Zhang Y, Dong C, Sun W, Yang P. Comparison of efficacy and safety of TACE combined with microwave ablation and TACE combined with cryoablation in the treatment of large hepatocellular carcinoma. Computational Intelligence and Neuroscience, 2022;2022(3):9783113(1-10).
34. Pachev A, Raynaud L, Paulatto L, Dioguardi Burgio M, Roche V, Garcia Alba C, Sibert A, Lagadec M, Kavafyan-Lasserre J, Paugam-Burtz C, Vilgrain V, Ronot M. Predictive factors of severe abdominal pain during and after transarterial chemoembolization for hepatocellular carcinoma. European Radiology, 2021;31(5):3267-3275.
35. Lu H, Zheng C, Liang B, Xiong B. Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis. BMC Cancer, 2021;21(1):513(1-9).
36. Gibo M, Hasuo K, Inoue A, Miura N, Murata S. Hepatic falciform artery: angiographic observations and significance. Abdom Imaging, 2001;26(5):515-9.